Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by
Crossref.
Muller, Claude P.
and
Mulders, Mick. N.
2002.
The Molecular Epidemiology of Human Viruses.
p.
237.
Mutapi, Francisca
and
Roddam, Andrew
2002.
p values for pathogens: statistical inference from infectious-disease data.
The Lancet Infectious Diseases,
Vol. 2,
Issue. 4,
p.
219.
Cox, Martin J.
2002.
A laboratory-based introduction to seroepidemiology and its use in vaccination programme design.
Journal of Biological Education,
Vol. 36,
Issue. 3,
p.
138.
Nardone, A
Gay, NJ
and
Edmunds, WJ
2002.
Congenital rubella: down but not out.
The Lancet,
Vol. 360,
Issue. 9335,
p.
804.
Amaku, M.
Coutinho, F. A. B.
Azevedo, R. S.
Burattini, M. N.
Lopez, L. F.
and
Massad, E.
2003.
Vaccination against rubella: Analysis of the temporal evolution of the age-dependent force of infection and the effects of different contact patterns.
Physical Review E,
Vol. 67,
Issue. 5,
MILLER, ELIZABETH
2003.
The Vaccine Book.
p.
37.
Stein, Claudia E.
Birmingham, Maureen
Kurian, Mary
Duclos, Philippe
and
Strebel, Peter
2003.
The Global Burden of Measles in the Year 2000—A Model that Uses Country‐Specific Indicators.
The Journal of Infectious Diseases,
Vol. 187,
Issue. s1,
p.
S8.
Vynnycky, E.
Gay, N.J.
and
Cutts, F.T.
2003.
The predicted impact of private sector MMR vaccination on the burden of Congenital Rubella Syndrome.
Vaccine,
Vol. 21,
Issue. 21-22,
p.
2708.
Bonanni, Paolo
Beutels, P.
Bechini, A.
and
Maci, M.
2003.
Valutazione economica dell’incremento della copertura vaccinale contro la pertosse in Toscana: una nota preliminare.
PharmacoEconomics Italian Research Articles,
Vol. 5,
Issue. S1,
p.
1.
Zotti, Carla Maria
Castella, A.
Charrier, L.
De Donno, A.
Lopalco, P. L.
and
Gabutti, G.
2003.
Valutazione economica della vaccinazione antimorbillo-parotite-rosolia in relazione al livello di copertura.
PharmacoEconomics Italian Research Articles,
Vol. 5,
Issue. S1,
p.
65.
Williams, John R
Manfredi, Piero
Butler, Alisa R
Ciofi degli Atti, Marta
and
Salmaso, Stefania
2003.
Heterogeneity in regional notification patterns and its impact on aggregate national case notification data: the example of measles in Italy.
BMC Public Health,
Vol. 3,
Issue. 1,
Garrido Álvarez, E.
Álvarez Pasquín, M.J.
Gómez Marco, J.
Martín Martín, S.
Kloppe Villegas, P.
and
Hernando López, T.
2004.
Seroprevalencia de anticuerpos antirrubéola en mujeres inmigrantes en edad fértil en 2 centros de salud de Madrid.
Vacunas,
Vol. 5,
Issue. 4,
p.
75.
Whitaker, H. J.
and
Farrington, C. P.
2004.
Estimation of infectious disease parameters from serological survey data: the impact of regular epidemics.
Statistics in Medicine,
Vol. 23,
Issue. 15,
p.
2429.
Scott, Susana
Mossong, Joel
Moss, William J.
Cutts, Felicity T.
Kasolo, Francis
Sinkala, Moses
and
Cousens, Simon
2004.
Estimating the force of measles virus infection from hospitalised cases in Lusaka, Zambia.
Vaccine,
Vol. 23,
Issue. 6,
p.
732.
Hethcote, Herbert W
Horby, Peter
and
McIntyre, Peter
2004.
Using computer simulations to compare pertussis vaccination strategies in Australia.
Vaccine,
Vol. 22,
Issue. 17-18,
p.
2181.
Tan, H.F
Tseng, H.F
Chang, C.K
Ke, D
and
Lee-Hsieh, J
2004.
The incidence of varicella in southern Taiwan: a life table method estimation among susceptible population.
Vaccine,
Vol. 22,
Issue. 21-22,
p.
2730.
Boubaker, S.Haddad
Ben Yahia, A
Bahri, O
and
Triki, H
2004.
Étude de l’infection par le virus de la rubéole chez l’enfant et l’adolescent en Tunisie.
Pathologie Biologie,
Vol. 52,
Issue. 1,
p.
11.
Manfredi, Piero
and
Williams, John R.
2004.
Realistic population dynamics in epidemiological models: the impact of population decline on the dynamics of childhood infectious diseases.
Mathematical Biosciences,
Vol. 192,
Issue. 2,
p.
153.
Van Rie, Annelies
and
Hethcote, Herbert W
2004.
Adolescent and adult pertussis vaccination: computer simulations of five new strategies.
Vaccine,
Vol. 22,
Issue. 23-24,
p.
3154.
Chihrin, Stephen
and
Loutfy, Mona R
2005.
Overview of antiviral and anti-inflammatory treatment for severe acute respiratory syndrome.
Expert Review of Anti-infective Therapy,
Vol. 3,
Issue. 2,
p.
251.